imatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 1423 152459-95-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • imatinib
  • gleevec
  • imatinib mesylate
  • imatinib mesilate
  • CGP-57-148B
  • CGP57148B
  • CGP-57148
  • CGP57148
  • STI-571
  • STI571
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
  • Molecular weight: 493.62
  • Formula: C29H31N7O
  • CLOGP: 4.38
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 86.28
  • ALOGS: -4.53
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.05 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 20.26 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 98 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 22 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 7, 2001 EMA Novartis Europharm Limited
May 10, 2001 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 1902.81 13.24 1745 41199 372636 63073442
Drug resistance 770.05 13.24 354 42590 22579 63423499
Blast crisis in myelogenous leukaemia 736.69 13.24 148 42796 409 63445669
Cytogenetic analysis abnormal 684.62 13.24 152 42792 768 63445310
Malignant neoplasm progression 490.84 13.24 422 42522 81699 63364379
Second primary malignancy 443.59 13.24 176 42768 7777 63438301
Periorbital oedema 360.17 13.24 138 42806 5546 63440532
Philadelphia chromosome positive 307.14 13.24 68 42876 338 63445740
Gene mutation identification test positive 275.42 13.24 52 42892 90 63445988
Chronic myeloid leukaemia recurrent 271.66 13.24 56 42888 183 63445895
Pleural effusion 230.11 13.24 299 42645 92911 63353167
Muscle spasms 227.34 13.24 391 42553 155759 63290319
Neoplasm malignant 208.34 13.24 168 42776 29693 63416385
Acute lymphocytic leukaemia recurrent 206.67 13.24 72 42872 2197 63443881
Oncologic complication 192.42 13.24 41 42903 164 63445914
Leukaemia recurrent 184.24 13.24 58 42886 1280 63444798
Chromosome analysis abnormal 183.40 13.24 37 42907 105 63445973
Eyelid oedema 166.59 13.24 98 42846 10381 63435697
Chronic myeloid leukaemia transformation 163.23 13.24 33 42911 95 63445983
Oedema 161.44 13.24 259 42685 97363 63348715
Eye swelling 148.95 13.24 126 42818 23792 63422286
Fluid retention 146.48 13.24 191 42753 59495 63386583
Gastric antral vascular ectasia 142.31 13.24 40 42904 587 63445491
Arthropathy 136.80 13.24 5 42939 234787 63211291
Rheumatoid arthritis 136.46 13.24 9 42935 253810 63192268
Haematotoxicity 134.29 13.24 82 42862 9294 63436784
Bone marrow failure 132.64 13.24 129 42815 29161 63416917
Nausea 128.88 13.24 1001 41943 853470 62592608
Pancytopenia 118.30 13.24 225 42719 96708 63349370
Anaemia 116.76 13.24 449 42495 292981 63153097
Disease progression 115.62 13.24 256 42688 122502 63323576
Face oedema 114.74 13.24 101 42843 20111 63425967
Systemic lupus erythematosus 113.49 13.24 7 42937 208911 63237167
Product substitution issue 109.44 13.24 89 42855 15907 63430171
Generalised oedema 108.20 13.24 88 42856 15730 63430348
Chronic myeloid leukaemia 107.65 13.24 45 42899 2273 63443805
Oedema peripheral 100.45 13.24 319 42625 189192 63256886
Conjunctival haemorrhage 97.72 13.24 48 42896 3539 63442539
Drug hypersensitivity 93.07 13.24 47 42897 310640 63135438
Metastases to liver 90.35 13.24 95 42849 23544 63422534
Pain 86.64 13.24 238 42706 740390 62705688
Cytogenetic abnormality 86.29 13.24 26 42918 493 63445585
Glossodynia 86.20 13.24 10 42934 178866 63267212
Normal newborn 85.17 13.24 59 42885 8282 63437796
Blast cell crisis 84.67 13.24 18 42926 71 63446007
Therapeutic product effect decreased 83.36 13.24 15 42929 193172 63252906
Swelling face 83.23 13.24 152 42792 63323 63382755
Thrombocytosis 81.06 13.24 50 42894 5768 63440310
Thrombocytopenia 80.56 13.24 255 42689 150902 63295176
Gene mutation 79.60 13.24 33 42911 1632 63444446
Pseudoporphyria 79.00 13.24 20 42924 191 63445887
Splenomegaly 78.27 13.24 63 42881 11094 63434984
Off label use 76.41 13.24 220 42724 674242 62771836
Completed suicide 75.84 13.24 6 42938 145667 63300411
Injection site pain 74.75 13.24 3 42941 129797 63316281
Graft versus host disease 74.18 13.24 50 42894 6713 63439365
Recurrent cancer 73.98 13.24 33 42911 1954 63444124
Pericardial effusion 73.41 13.24 96 42848 29962 63416116
Vomiting 72.81 13.24 635 42309 558982 62887096
Discomfort 72.19 13.24 13 42931 167361 63278717
Diarrhoea 71.15 13.24 767 42177 714599 62731479
Wound 69.73 13.24 13 42931 163250 63282828
Bone pain 69.31 13.24 129 42815 54512 63391566
Growth retardation 68.95 13.24 28 42916 1313 63444765
Joint swelling 68.94 13.24 72 42872 327594 63118484
Product use issue 66.54 13.24 33 42911 220487 63225591
Chronic graft versus host disease 65.61 13.24 35 42909 3067 63443011
Sinusitis 65.31 13.24 36 42908 226617 63219461
Gastrointestinal stromal tumour 63.42 13.24 25 42919 1084 63444994
Lower respiratory tract infection 62.25 13.24 8 42936 132299 63313779
White blood cell count increased 62.03 13.24 115 42829 48446 63397632
Pneumatosis intestinalis 61.91 13.24 31 42913 2382 63443696
Therapeutic response decreased 60.93 13.24 131 42813 61394 63384684
Exposure via father 60.13 13.24 17 42927 255 63445823
Neoplasm recurrence 59.30 13.24 31 42913 2607 63443471
Neoplasm progression 59.26 13.24 96 42848 36332 63409746
Drug intolerance 59.14 13.24 384 42560 308277 63137801
Leukocytosis 58.98 13.24 80 42864 25855 63420223
Haemoglobin decreased 58.84 13.24 224 42720 145261 63300817
Condition aggravated 58.32 13.24 115 42829 402102 63043976
Leukaemia 58.21 13.24 36 42908 4172 63441906
Neutropenia 57.75 13.24 253 42691 174752 63271326
Myalgia 55.51 13.24 221 42723 146308 63299770
Hepatotoxicity 55.40 13.24 94 42850 36947 63409131
Platelet count increased 55.25 13.24 64 42880 17647 63428431
Pericarditis 55.07 13.24 11 42933 131568 63314510
Polymerase chain reaction positive 54.81 13.24 14 42930 139 63445939
Confusional state 54.28 13.24 48 42896 236332 63209746
Rash 54.07 13.24 598 42346 560273 62885805
Exposure via body fluid 50.21 13.24 18 42926 598 63445480
Eye oedema 49.51 13.24 23 42921 1497 63444581
Musculoskeletal stiffness 49.41 13.24 32 42912 184586 63261492
Eye haemorrhage 49.30 13.24 43 42901 8453 63437625
Metastases to peritoneum 49.02 13.24 30 42914 3412 63442666
Cardiac output decreased 48.96 13.24 20 42924 952 63445126
Jaundice 48.82 13.24 78 42866 29173 63416905
Psoriatic arthropathy 46.99 13.24 4 42940 91516 63354562
Nasopharyngitis 46.87 13.24 62 42882 254195 63191883
Platelet count decreased 46.28 13.24 178 42766 115944 63330134
Fall 45.75 13.24 126 42818 392208 63053870
Helicobacter infection 45.15 13.24 5 42939 92780 63353298
Therapy non-responder 45.02 13.24 133 42811 75768 63370310
Hypotension 44.83 13.24 72 42872 272532 63173546
Cytopenia 41.46 13.24 45 42899 11556 63434522
Tumour excision 41.08 13.24 14 42930 399 63445679
Ascites 40.64 13.24 87 42857 40641 63405437
Intentional product use issue 40.30 13.24 18 42926 127874 63318204
Asthma 40.13 13.24 18 42926 127543 63318535
Toxic skin eruption 39.26 13.24 46 42898 12839 63433239
Myelofibrosis 39.23 13.24 19 42925 1358 63444720
Blood lactate dehydrogenase increased 39.07 13.24 62 42882 23054 63423024
Blast cells present 39.02 13.24 14 42930 466 63445612
Loss of personal independence in daily activities 38.94 13.24 9 42935 97281 63348797
Peripheral arterial occlusive disease 38.91 13.24 28 42916 4173 63441905
Hypersensitivity 38.76 13.24 88 42856 292597 63153481
Leukopenia 38.07 13.24 127 42817 77163 63368915
Erythrocyanosis 37.80 13.24 6 42938 0 63446078
Acute graft versus host disease 37.59 13.24 28 42916 4400 63441678
Psoriasis 36.95 13.24 7 42937 86950 63359128
Breast cancer 36.90 13.24 93 42851 48290 63397788
Blast cell count increased 36.23 13.24 13 42931 433 63445645
Pulse waveform abnormal 36.13 13.24 9 42935 80 63445998
Ankle brachial index decreased 36.13 13.24 9 42935 80 63445998
Carotid intima-media thickness increased 35.73 13.24 9 42935 84 63445994
White blood cell count decreased 35.63 13.24 187 42757 138917 63307161
Periorbital swelling 35.46 13.24 23 42921 2895 63443183
Chloroma 35.41 13.24 11 42933 232 63445846
Mobility decreased 35.23 13.24 19 42925 121140 63324938
Fibromyalgia 35.20 13.24 6 42938 80414 63365664
Urinary tract infection 34.70 13.24 80 42864 264604 63181474
Therapeutic response delayed 34.60 13.24 14 42930 650 63445428
Cardiotoxicity 34.19 13.24 35 42909 8403 63437675
Skin fragility 34.16 13.24 14 42930 672 63445406
Aplasia 34.09 13.24 26 42918 4233 63441845
Right ventricular failure 33.13 13.24 49 42895 17139 63428939
Bone marrow transplant 33.10 13.24 14 42930 728 63445350
Surgery 32.75 13.24 74 42870 35838 63410240
Hepatic enzyme increased 31.80 13.24 55 42889 202273 63243805
Trisomy 8 31.50 13.24 5 42939 0 63446078
Chronic myeloid leukaemia (in remission) 31.50 13.24 5 42939 0 63446078
Folliculitis 31.32 13.24 5 42939 70312 63375766
Jaw operation 31.24 13.24 14 42930 838 63445240
Oral pigmentation 31.21 13.24 6 42938 12 63446066
Injury 30.90 13.24 6 42938 73241 63372837
Impaired healing 29.93 13.24 16 42928 102526 63343552
Arthritis 29.78 13.24 21 42923 115900 63330178
Overdose 29.36 13.24 21 42923 115057 63331021
Inappropriate schedule of product administration 29.22 13.24 17 42927 103948 63342130
Bone marrow oedema 28.96 13.24 15 42929 1237 63444841
Left ventricular dysfunction 28.82 13.24 38 42906 11950 63434128
Irritable bowel syndrome 28.59 13.24 10 42934 82402 63363676
Tumour necrosis 28.58 13.24 13 42931 806 63445272
Exposure via partner 28.30 13.24 8 42936 120 63445958
Tumour haemorrhage 27.90 13.24 16 42928 1615 63444463
Lacrimation increased 27.78 13.24 50 42894 20581 63425497
Intentional overdose 27.49 13.24 8 42936 74144 63371934
Type 2 diabetes mellitus 27.44 13.24 5 42939 63863 63382215
Typhoid fever 27.41 13.24 6 42938 28 63446050
Abortion spontaneous 27.31 13.24 82 42862 47113 63398965
Knee arthroplasty 26.17 13.24 3 42941 54203 63391875
Hypertension 26.04 13.24 99 42845 279204 63166874
Hepatic necrosis 25.64 13.24 25 42919 5662 63440416
Skin toxicity 25.64 13.24 23 42921 4691 63441387
Blood cholesterol increased 25.55 13.24 16 42928 94016 63352062
Chylothorax 25.45 13.24 9 42935 287 63445791
Disseminated intravascular coagulation 25.43 13.24 46 42898 19005 63427073
Pubertal failure 25.39 13.24 5 42939 12 63446066
Slit-lamp tests abnormal 25.20 13.24 4 42940 0 63446078
Transdifferentiation of neoplasm 25.10 13.24 5 42939 13 63446065
Obliterative bronchiolitis 24.20 13.24 16 42928 2079 63443999
Abortion 23.95 13.24 17 42927 2479 63443599
Adverse event 23.77 13.24 8 42936 67551 63378527
Blood pressure increased 23.72 13.24 46 42898 162016 63284062
Therapy cessation 23.70 13.24 59 42885 30398 63415680
Chronic graft versus host disease in skin 23.31 13.24 11 42933 742 63445336
Urine odour abnormal 23.21 13.24 25 42919 6364 63439714
K-ras gene mutation 23.08 13.24 5 42939 22 63446056
Papilloedema 22.89 13.24 20 42924 3940 63442138
Urticaria 22.62 13.24 49 42895 165753 63280325
Cardiac failure 22.24 13.24 119 42825 89023 63357055
Neoplasm 22.01 13.24 26 42918 7319 63438759
Arthralgia 21.68 13.24 264 42680 569446 62876632
Pyrexia 21.62 13.24 442 42502 470036 62976042
Acute lymphocytic leukaemia 21.56 13.24 16 42928 2500 63443578
Dizziness 21.36 13.24 187 42757 429738 63016340
Anaphylactic reaction 21.30 13.24 9 42935 66091 63379987
Stem cell transplant 21.26 13.24 14 42930 1808 63444270
Osteoarthritis 21.10 13.24 20 42924 95323 63350755
Computerised tomogram abnormal 21.05 13.24 15 42929 2202 63443876
Anxiety 20.99 13.24 76 42868 217465 63228613
Gastrointestinal toxicity 20.91 13.24 26 42918 7715 63438363
Abortion induced 20.90 13.24 30 42914 10212 63435866
Insomnia 20.90 13.24 75 42869 215177 63230901
Hepatic failure 20.67 13.24 62 42882 35594 63410484
Blood creatine phosphokinase increased 20.65 13.24 56 42888 30374 63415704
Abdominal discomfort 20.50 13.24 130 42814 320755 63125323
Basophilia 20.49 13.24 4 42940 9 63446069
Pyoderma gangrenosum 20.34 13.24 18 42926 3607 63442471
Myelocytosis 20.19 13.24 4 42940 10 63446068
Blood bilirubin increased 20.06 13.24 63 42881 37077 63409001
Metastasis 20.05 13.24 21 42923 5176 63440902
Philadelphia positive chronic myeloid leukaemia 20.02 13.24 5 42939 45 63446033
Therapy partial responder 19.99 13.24 30 42914 10628 63435450
Blood test abnormal 19.93 13.24 37 42907 15592 63430486
Skin hypopigmentation 19.82 13.24 10 42934 781 63445297
Intracardiac mass 19.63 13.24 5 42939 49 63446029
Swelling 19.47 13.24 108 42836 275270 63170808
Agitation 19.47 13.24 8 42936 59749 63386329
Peritoneal lesion 19.42 13.24 4 42940 13 63446065
Therapy interrupted 19.35 13.24 57 42887 32398 63413680
Suicidal ideation 19.32 13.24 9 42935 62412 63383666
Aspiration pleural cavity 18.95 13.24 10 42934 857 63445221
Headache 18.92 13.24 308 42636 632933 62813145
Hepatomegaly 18.88 13.24 31 42913 11858 63434220
Ocular hyperaemia 18.82 13.24 48 42896 25096 63420982
Gastrointestinal angiectasia 18.64 13.24 5 42939 61 63446017
Dengue fever 18.55 13.24 9 42935 646 63445432
Exophthalmos 18.54 13.24 12 42932 1504 63444574
Back pain 18.46 13.24 104 42840 264041 63182037
Hallucination 18.42 13.24 7 42937 54810 63391268
Product dose omission issue 18.19 13.24 89 42855 234224 63211854
Sleep disorder 18.18 13.24 17 42927 81549 63364529
Wheezing 17.91 13.24 23 42921 95572 63350506
Tumour lysis syndrome 17.86 13.24 26 42918 8964 63437114
Acquired gene mutation 17.77 13.24 10 42934 973 63445105
Delirium 17.76 13.24 6 42938 50535 63395543
Skin mass 17.71 13.24 21 42923 5934 63440144
Fibrin degradation products increased 17.71 13.24 6 42938 168 63445910
Aspartate aminotransferase increased 17.64 13.24 113 42831 90164 63355914
Somnolence 17.52 13.24 62 42882 178623 63267455
Flushing 17.51 13.24 15 42929 75072 63371006
Scleroderma 17.48 13.24 20 42924 5442 63440636
Influenza like illness 17.30 13.24 12 42932 66812 63379266
Tremor 17.29 13.24 40 42904 132199 63313879
Scleroderma-like reaction 17.16 13.24 5 42939 84 63445994
Ejection fraction decreased 17.10 13.24 43 42901 22289 63423789
Hepatitis fulminant 17.08 13.24 16 42928 3448 63442630
Morphoea 16.96 13.24 7 42937 342 63445736
Pulmonary interstitial emphysema syndrome 16.82 13.24 3 42941 3 63446075
Abdominal distension 16.67 13.24 108 42836 86507 63359571
Desmoid tumour 16.63 13.24 5 42939 94 63445984
Pigmentation disorder 16.58 13.24 18 42926 4621 63441457
Eosinophilia 16.58 13.24 43 42901 22713 63423365
Liver disorder 16.46 13.24 76 42868 53611 63392467
Hyponatraemia 16.16 13.24 32 42912 111868 63334210
Blood creatinine increased 15.98 13.24 108 42836 87736 63358342
Lichen planus 15.97 13.24 13 42931 2325 63443753
Exposure during pregnancy 15.88 13.24 168 42776 155379 63290699
Complex regional pain syndrome 15.88 13.24 13 42931 2344 63443734
Myelodysplastic syndrome 15.81 13.24 35 42909 16719 63429359
Blood blister 15.77 13.24 12 42932 1946 63444132
Syncope 15.75 13.24 35 42909 117350 63328728
Microangiopathy 15.71 13.24 10 42934 1218 63444860
Myeloid maturation arrest 15.61 13.24 3 42941 6 63446072
Acute myeloid leukaemia recurrent 15.45 13.24 11 42933 1612 63444466
Cystitis 15.43 13.24 9 42935 54982 63391096
Red blood cell count decreased 15.12 13.24 61 42883 40584 63405494
Central nervous system leukaemia 14.82 13.24 5 42939 138 63445940
Concomitant disease aggravated 14.79 13.24 24 42920 9088 63436990
Adenovirus reactivation 14.56 13.24 5 42939 146 63445932
Capillary leak syndrome 14.54 13.24 12 42932 2188 63443890
Lichenoid keratosis 14.52 13.24 11 42933 1772 63444306
Hepatic mass 14.43 13.24 11 42933 1789 63444289
Giardiasis 14.40 13.24 4 42940 56 63446022
Paternal drugs affecting foetus 14.34 13.24 4 42940 57 63446021
Polyhydramnios 14.21 13.24 12 42932 2259 63443819
Adenocarcinoma gastric 14.16 13.24 7 42937 523 63445555
Retroplacental haematoma 14.15 13.24 5 42939 159 63445919
Aspergillus infection 14.08 13.24 22 42922 8071 63438007
Cellulitis 14.07 13.24 21 42923 81937 63364141
Blood alkaline phosphatase increased 14.05 13.24 62 42882 42905 63403173
Acute leukaemia 13.93 13.24 9 42935 1125 63444953
Growth failure 13.82 13.24 6 42938 333 63445745
Therapy responder 13.75 13.24 6 42938 337 63445741
Food interaction 13.75 13.24 8 42936 830 63445248
Disease recurrence 13.74 13.24 46 42898 27984 63418094
Hepatic neoplasm 13.72 13.24 11 42933 1925 63444153
Hyperkalaemia 13.68 13.24 10 42934 54193 63391885
Complications of transplant surgery 13.59 13.24 5 42939 179 63445899
Product coating issue 13.42 13.24 4 42940 73 63446005
Lung infiltration 13.41 13.24 30 42914 14433 63431645
Skull fractured base 13.37 13.24 4 42940 74 63446004
Oxygen saturation 13.36 13.24 5 42939 188 63445890
Alopecia 13.34 13.24 155 42789 337381 63108697
Stenotrophomonas infection 13.28 13.24 11 42933 2016 63444062

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 2625.54 12.31 2889 43205 395160 34515677
Drug resistance 1015.02 12.31 550 45544 25377 34885460
Blast crisis in myelogenous leukaemia 791.43 12.31 179 45915 425 34910412
Second primary malignancy 623.72 12.31 271 45823 7615 34903222
Cytogenetic analysis abnormal 566.59 12.31 142 45952 597 34910240
Malignant neoplasm progression 552.79 12.31 629 45465 87417 34823420
Neoplasm malignant 365.36 12.31 261 45833 19644 34891193
Philadelphia chromosome positive 337.45 12.31 82 46012 294 34910543
Drug intolerance 284.45 12.31 371 45723 59199 34851638
Pleural effusion 260.85 12.31 420 45674 81126 34829711
Oncologic complication 242.86 12.31 62 46032 285 34910552
Acute lymphocytic leukaemia recurrent 241.87 12.31 105 45989 2939 34907898
Gene mutation 196.95 12.31 73 46021 1335 34909502
Chronic myeloid leukaemia recurrent 190.81 12.31 46 46048 158 34910679
Gene mutation identification test positive 186.41 12.31 43 46051 115 34910722
Chronic myeloid leukaemia transformation 185.34 12.31 43 46051 119 34910718
Chromosome analysis abnormal 183.53 12.31 43 46051 126 34910711
Periorbital oedema 161.53 12.31 85 46009 3677 34907160
Metastases to liver 157.08 12.31 136 45958 13527 34897310
Leukaemia recurrent 155.96 12.31 64 46030 1551 34909286
Therapeutic response decreased 145.12 12.31 186 45908 29127 34881710
Recurrent cancer 127.29 12.31 53 46041 1334 34909503
Oedema 122.70 12.31 218 45876 45523 34865314
Gastrointestinal stromal tumour 119.46 12.31 46 46048 938 34909899
Drug abuse 112.90 12.31 4 46090 99092 34811745
Muscle spasms 107.54 12.31 277 45817 74724 34836113
Blast cell crisis 105.53 12.31 25 46069 78 34910759
White blood cell count increased 103.83 12.31 191 45903 40960 34869877
Eyelid oedema 100.46 12.31 70 46024 5054 34905783
Chronic graft versus host disease 93.44 12.31 63 46031 4310 34906527
Off label use 92.59 12.31 267 45827 419257 34491580
Neoplasm recurrence 91.42 12.31 49 46045 2200 34908637
Completed suicide 89.05 12.31 12 46082 98156 34812681
Neoplasm progression 84.06 12.31 127 45967 23173 34887664
Hypotension 83.29 12.31 102 45992 221547 34689290
Polymerase chain reaction positive 83.21 12.31 22 46072 119 34910718
Overdose 82.91 12.31 11 46083 91048 34819789
Therapy non-responder 82.02 12.31 168 45926 38978 34871859
Blast cells present 81.23 12.31 29 46065 474 34910363
Bone marrow necrosis 80.50 12.31 23 46071 173 34910664
Gastric antral vascular ectasia 77.59 12.31 26 46068 348 34910489
Splenomegaly 73.34 12.31 95 45999 15022 34895815
Face oedema 73.21 12.31 83 46011 11433 34899404
Fluid retention 70.59 12.31 127 45967 26760 34884077
Acute kidney injury 70.18 12.31 190 45904 304798 34606039
Necrotising panniculitis 67.40 12.31 15 46079 32 34910805
Disease progression 66.84 12.31 301 45793 107776 34803061
Product substitution issue 64.59 12.31 73 46021 10022 34900815
Myelofibrosis 62.42 12.31 34 46060 1577 34909260
Chronic myeloid leukaemia 62.29 12.31 38 46056 2186 34908651
Bradycardia 62.15 12.31 12 46082 75406 34835431
Fall 61.84 12.31 108 45986 202777 34708060
Treatment failure 61.32 12.31 167 45927 46530 34864307
Clonal evolution 61.06 12.31 17 46077 115 34910722
Graft versus host disease 58.57 12.31 71 46023 10498 34900339
Thrombocytopenia 57.14 12.31 377 45717 155870 34754967
Blast cell count increased 56.88 12.31 28 46066 1050 34909787
Acquired gene mutation 56.42 12.31 30 46064 1325 34909512
Central nervous system leukaemia 55.85 12.31 19 46075 267 34910570
Scleroderma 54.94 12.31 31 46063 1541 34909296
Bone pain 54.67 12.31 98 45996 20588 34890249
Confusional state 53.39 12.31 67 46027 144093 34766744
Metastases to peritoneum 52.91 12.31 32 46062 1812 34909025
Cytogenetic abnormality 52.52 12.31 25 46069 870 34909967
Bone marrow failure 51.47 12.31 117 45977 29136 34881701
Endocarditis noninfective 46.79 12.31 14 46080 126 34910711
Desmoid tumour 46.19 12.31 13 46081 92 34910745
Haemoglobin decreased 44.48 12.31 292 45802 120480 34790357
Hyperkalaemia 44.29 12.31 18 46076 69371 34841466
Surgery 43.89 12.31 72 46022 14085 34896752
Central nervous system neoplasm 43.65 12.31 12 46082 77 34910760
Typhoid fever 43.55 12.31 10 46084 26 34910811
Inappropriate schedule of product administration 43.42 12.31 14 46080 62282 34848555
Platelet count decreased 43.21 12.31 288 45806 119429 34791408
Intentional overdose 42.95 12.31 4 46090 43670 34867167
Exposure via father 42.87 12.31 13 46081 123 34910714
Pulmonary embolism 42.01 12.31 34 46060 89712 34821125
Toxicity to various agents 41.49 12.31 131 45963 200231 34710606
Hallucination 38.79 12.31 10 46084 51488 34859349
Loss of therapeutic response 38.64 12.31 18 46076 596 34910241
Accident 38.41 12.31 40 46054 5007 34905830
Pituitary apoplexy 38.15 12.31 10 46084 52 34910785
Nausea 38.04 12.31 644 45450 339264 34571573
Somnolence 37.72 12.31 55 46039 111061 34799776
Pericardial effusion 37.28 12.31 93 46001 24569 34886268
Tumour haemorrhage 37.13 12.31 31 46063 2931 34907906
Generalised oedema 36.98 12.31 62 46032 12346 34898491
Tumour necrosis 36.05 12.31 22 46072 1266 34909571
Osteonecrosis of external auditory canal 35.87 12.31 9 46085 38 34910799
Drug hypersensitivity 35.86 12.31 32 46062 80497 34830340
Tumour rupture 34.56 12.31 13 46081 248 34910589
Syncope 34.36 12.31 42 46052 91409 34819428
Colon cancer 33.98 12.31 49 46045 8572 34902265
Renal tuberculosis 33.80 12.31 6 46088 0 34910837
Gastrectomy 33.26 12.31 11 46083 141 34910696
Malaria 32.80 12.31 12 46082 211 34910626
Tuberculosis 32.71 12.31 48 46046 8529 34902308
Delirium 32.26 12.31 9 46085 43982 34866855
Prostate cancer 32.03 12.31 120 45974 39529 34871308
Tumour excision 31.74 12.31 11 46083 164 34910673
Graft versus host disease in eye 31.28 12.31 12 46082 242 34910595
Anxiety 31.09 12.31 52 46042 99376 34811461
Chronic graft versus host disease in skin 30.81 12.31 18 46076 956 34909881
Blood pressure increased 30.49 12.31 43 46051 88059 34822778
Condition aggravated 30.49 12.31 140 45954 192056 34718781
Optic neuritis 30.25 12.31 30 46064 3544 34907293
Deep vein thrombosis 30.18 12.31 25 46069 65223 34845614
Eye swelling 29.86 12.31 50 46044 9945 34900892
Ascites 29.71 12.31 131 45963 46440 34864397
Oral pigmentation 29.64 12.31 6 46088 6 34910831
Rhabdomyolysis 29.27 12.31 28 46066 68135 34842702
Gastrointestinal toxicity 29.10 12.31 26 46068 2693 34908144
Transformation to acute myeloid leukaemia 29.06 12.31 16 46078 758 34910079
Rash 28.98 12.31 433 45661 222319 34688518
Growth retardation 28.85 12.31 22 46072 1826 34909011
Oedema peripheral 28.64 12.31 262 45832 119550 34791287
Metabolic acidosis 28.41 12.31 11 46083 43669 34867168
Cytopenia 28.29 12.31 56 46038 12667 34898170
Seizure 28.24 12.31 60 46034 104797 34806040
Loss of CAR T-cell persistence 28.20 12.31 7 46087 28 34910809
Stem cell transplant 28.09 12.31 23 46071 2116 34908721
Dizziness 28.07 12.31 171 45923 218350 34692487
Tremor 27.90 12.31 41 46053 82546 34828291
Intentional product use issue 27.56 12.31 23 46071 59793 34851044
Pneumonia 27.54 12.31 326 45768 362301 34548536
Gastric cancer 27.31 12.31 38 46056 6431 34904406
Intentional product misuse 27.25 12.31 13 46081 45598 34865239
Pulmonary aplasia 27.22 12.31 6 46088 12 34910825
Pigmentation disorder 27.20 12.31 24 46070 2445 34908392
Hyperhidrosis 27.14 12.31 36 46058 75656 34835181
Flushing 27.04 12.31 5 46089 32415 34878422
Pemphigus 26.75 12.31 20 46074 1611 34909226
Metamyelocyte count increased 26.43 12.31 12 46082 374 34910463
Pancytopenia 25.81 12.31 214 45880 94943 34815894
Chloroma 25.80 12.31 13 46081 513 34910324
Skin hypopigmentation 25.77 12.31 11 46083 295 34910542
Janus kinase 2 mutation 25.50 12.31 6 46088 18 34910819
Demyelination 25.36 12.31 26 46068 3195 34907642
Agitation 25.32 12.31 23 46071 57376 34853461
Chronic obstructive pulmonary disease 24.86 12.31 17 46077 48901 34861936
Anaphylactic reaction 24.85 12.31 6 46088 32295 34878542
Drug clearance decreased 24.83 12.31 20 46074 1798 34909039
Stress 24.63 12.31 5 46089 30342 34880495
Acoustic neuroma 24.56 12.31 9 46085 159 34910678
Haematotoxicity 24.49 12.31 41 46053 8153 34902684
Myopathy toxic 24.47 12.31 13 46081 573 34910264
Product dose omission issue 24.23 12.31 79 46015 119632 34791205
Anaemia 23.84 12.31 436 45658 232899 34677938
Bone marrow disorder 23.51 12.31 19 46075 1716 34909121
Dehydration 23.48 12.31 90 46004 129879 34780958
Cardiac arrest 23.48 12.31 58 46036 96101 34814736
Aggression 23.44 12.31 11 46083 38953 34871884
Pseudoporphyria 23.43 12.31 11 46083 371 34910466
Suicidal ideation 23.39 12.31 12 46082 40376 34870461
International normalised ratio increased 23.32 12.31 17 46077 47310 34863527
Bone neoplasm 23.26 12.31 10 46084 273 34910564
Blindness 23.16 12.31 57 46037 14929 34895908
Post embolisation syndrome 23.10 12.31 7 46087 66 34910771
Wheezing 22.96 12.31 13 46081 41389 34869448
Trisomy 8 22.83 12.31 7 46087 69 34910768
Right ventricular diastolic collapse 22.74 12.31 7 46087 70 34910767
Atrial fibrillation 22.60 12.31 84 46010 122309 34788528
Acute aortic syndrome 22.53 12.31 4 46090 0 34910837
C-kit gene mutation 22.53 12.31 4 46090 0 34910837
Philadelphia chromosome negative 22.53 12.31 4 46090 0 34910837
Spleen palpable 22.53 12.31 4 46090 0 34910837
Leukaemic infiltration 22.39 12.31 8 46086 131 34910706
Blood lactate dehydrogenase increased 22.38 12.31 74 46020 22916 34887921
Cardio-respiratory arrest 22.25 12.31 24 46070 55249 34855588
Neuropathy peripheral 22.12 12.31 48 46046 83215 34827622
Urticaria 22.02 12.31 30 46064 62347 34848490
Bone marrow transplant 21.90 12.31 15 46079 1053 34909784
Concomitant disease aggravated 21.88 12.31 32 46062 5669 34905168
Polycythaemia vera 21.75 12.31 10 46084 321 34910516
Drug interaction 21.70 12.31 192 45902 225754 34685083
Hyponatraemia 21.69 12.31 48 46046 82643 34828194
Ocular myasthenia 21.59 12.31 9 46085 227 34910610
Large intestine infection 21.37 12.31 17 46077 1501 34909336
Encephalopathy 21.20 12.31 10 46084 35309 34875528
Medication error 21.19 12.31 4 46090 25561 34885276
Peripheral arterial occlusive disease 21.15 12.31 32 46062 5842 34904995
Therapy partial responder 20.99 12.31 42 46052 9574 34901263
Myelocyte count increased 20.77 12.31 10 46084 357 34910480
Dengue fever 20.75 12.31 9 46085 251 34910586
Suicide attempt 20.68 12.31 13 46081 39103 34871734
Therapeutic product effect decreased 20.61 12.31 10 46084 34733 34876104
Epistaxis 20.58 12.31 28 46066 58223 34852614
Loss of personal independence in daily activities 20.53 12.31 9 46085 33170 34877667
Complications of transplant surgery 20.42 12.31 11 46083 499 34910338
Psoriasis 20.38 12.31 13 46081 38799 34872038
Rectosigmoid cancer 20.34 12.31 8 46086 173 34910664
Pericardial excision 20.30 12.31 4 46090 3 34910834
Retroperitoneal fibrosis 19.90 12.31 10 46084 392 34910445
Arterial disorder 19.68 12.31 15 46079 1244 34909593
Mental status changes 19.66 12.31 13 46081 38070 34872767
Myalgia 19.61 12.31 183 45911 83927 34826910
Lactobacillus infection 19.35 12.31 9 46085 297 34910540
B-cell small lymphocytic lymphoma 19.30 12.31 8 46086 199 34910638
Constipation 19.28 12.31 104 45990 136878 34773959
Lactic acidosis 19.16 12.31 11 46083 34761 34876076
Thrombosis 19.12 12.31 23 46071 50435 34860402
Musculoskeletal stiffness 19.09 12.31 20 46074 46660 34864177
Heart rate decreased 19.04 12.31 9 46085 31736 34879101
Graft versus host disease in lung 19.02 12.31 11 46083 573 34910264
Leukocytosis 18.74 12.31 72 46022 23993 34886844
Oropharyngeal pain 18.47 12.31 12 46082 35473 34875364
Hepatic calcification 18.27 12.31 9 46085 338 34910499
Product prescribing error 18.15 12.31 4 46090 22923 34887914
Colitis 18.03 12.31 14 46080 37736 34873101
Dropped head syndrome 18.03 12.31 7 46087 146 34910691
Blood pressure decreased 17.96 12.31 25 46069 51490 34859347
Chest expansion decreased 17.94 12.31 7 46087 148 34910689
Tachycardia 17.81 12.31 55 46039 84717 34826120
Platelet count increased 17.75 12.31 39 46055 9487 34901350
Adrenomegaly 17.75 12.31 9 46085 360 34910477
Costal cartilage fracture 17.72 12.31 8 46086 246 34910591
Leukostasis syndrome 17.69 12.31 5 46089 36 34910801
Orbital oedema 17.68 12.31 7 46087 154 34910683
Vomiting 17.61 12.31 439 45655 247182 34663655
Bone marrow oedema 17.59 12.31 11 46083 661 34910176
Therapy change 17.58 12.31 21 46073 3056 34907781
Diaphragmatic disorder 17.36 12.31 14 46080 1261 34909576
Neoplasm 17.21 12.31 28 46066 5439 34905398
Skin toxicity 17.14 12.31 26 46068 4758 34906079
Essential thrombocythaemia 17.02 12.31 5 46089 42 34910795
Metastasis 16.98 12.31 24 46070 4120 34906717
Platelet dysfunction 16.92 12.31 8 46086 274 34910563
Hepatic embolisation 16.90 12.31 3 46091 0 34910837
Cytoreductive surgery 16.90 12.31 3 46091 0 34910837
Intestinal congestion 16.76 12.31 4 46090 13 34910824
Multiple-drug resistance 16.72 12.31 27 46067 5212 34905625
Asthma 16.64 12.31 19 46075 42637 34868200
Gelatinous transformation of the bone marrow 16.53 12.31 4 46090 14 34910823
Abscess drainage 16.50 12.31 8 46086 290 34910547
Acinetobacter sepsis 16.33 12.31 5 46089 49 34910788
Marrow hyperplasia 16.32 12.31 13 46081 1150 34909687
Coma 16.09 12.31 22 46072 45656 34865181
Drug-induced liver injury 16.06 12.31 9 46085 28823 34882014
Biopsy bone marrow abnormal 15.99 12.31 8 46086 311 34910526
Drug dependence 15.91 12.31 6 46088 24211 34886626
Presyncope 15.76 12.31 3 46091 19056 34891781
Nasopharyngitis 15.71 12.31 44 46050 69924 34840913
Cerebral toxoplasmosis 15.60 12.31 15 46079 1706 34909131
Lichen sclerosus 15.56 12.31 4 46090 19 34910818
Metastases to bladder 15.27 12.31 5 46089 62 34910775
Back pain 15.24 12.31 96 45998 121693 34789144
Foetal death 15.13 12.31 7 46087 228 34910609
Leukaemia 15.07 12.31 24 46070 4579 34906258
Pneumonia aspiration 14.94 12.31 20 46074 41883 34868954
Lactose intolerance 14.92 12.31 13 46081 1302 34909535
Bence Jones proteinuria 14.82 12.31 3 46091 3 34910834
Hydrocele operation 14.82 12.31 3 46091 3 34910834
Breast oedema 14.82 12.31 3 46091 3 34910834
Parakeratosis 14.79 12.31 6 46088 141 34910696
Lipase increased 14.75 12.31 36 46058 9380 34901457
Growth failure 14.72 12.31 5 46089 70 34910767
Chills 14.70 12.31 56 46038 80987 34829850
Diabetic ketoacidosis 14.57 12.31 3 46091 18029 34892808
Metastases to heart 14.48 12.31 6 46088 149 34910688
Chronic graft versus host disease in intestine 14.38 12.31 7 46087 256 34910581
Hyperkeratosis 14.32 12.31 21 46073 3728 34907109
Angioedema 14.20 12.31 17 46077 37357 34873480
Disease recurrence 14.12 12.31 61 46033 21429 34889408
Blood creatinine increased 14.06 12.31 189 45905 94787 34816050
Urinary tract infection 14.06 12.31 60 46034 84021 34826816
Product use issue 14.01 12.31 40 46054 63176 34847661
Swelling face 13.98 12.31 64 46030 23041 34887796
Cardiogenic shock 13.86 12.31 9 46085 26609 34884228
Bladder neoplasm surgery 13.78 12.31 4 46090 32 34910805
Foetal exposure during pregnancy 13.78 12.31 18 46076 38083 34872754
Abdominal pain 13.75 12.31 297 45797 163321 34747516
Skin depigmentation 13.64 12.31 8 46086 428 34910409
Clear cell sarcoma of soft tissue 13.61 12.31 3 46091 6 34910831
Fibrin D dimer decreased 13.61 12.31 3 46091 6 34910831
Aspiration bone marrow 13.61 12.31 3 46091 6 34910831
Therapy responder 13.52 12.31 6 46088 177 34910660
Lung neoplasm malignant 13.51 12.31 52 46042 17343 34893494
Oxygen saturation decreased 13.50 12.31 32 46062 53786 34857051
Eye haemorrhage 13.48 12.31 22 46072 4283 34906554
Insomnia 13.47 12.31 81 46013 103826 34807011
Unresponsive to stimuli 13.45 12.31 10 46084 27559 34883278
Hepatotoxicity 13.37 12.31 60 46034 21425 34889412
Unevaluable event 13.28 12.31 14 46080 32576 34878261
Toxic epidermal necrolysis 13.19 12.31 6 46088 21640 34889197
Periorbital swelling 13.19 12.31 9 46085 628 34910209
Orthostatic hypotension 13.18 12.31 9 46085 25910 34884927
Psychotic disorder 13.10 12.31 8 46086 24444 34886393
Acute lymphocytic leukaemia 13.10 12.31 18 46076 3011 34907826
Dysarthria 13.02 12.31 16 46078 34766 34876071
Ventricular fibrillation 13.02 12.31 7 46087 22947 34887890
Blood pressure systolic increased 13.02 12.31 7 46087 22945 34887892
Conjunctival haemorrhage 12.98 12.31 18 46076 3037 34907800
Lacrimation increased 12.83 12.31 32 46062 8450 34902387
Alveolar proteinosis 12.82 12.31 8 46086 479 34910358
Pseudomyxoma peritonei 12.75 12.31 3 46091 9 34910828
Bone development abnormal 12.73 12.31 4 46090 43 34910794
Paternal exposure during pregnancy 12.73 12.31 4 46090 43 34910794
Generalised tonic-clonic seizure 12.70 12.31 6 46088 21168 34889669
Sinusitis 12.61 12.31 22 46072 41380 34869457
Transitional cell carcinoma 12.61 12.31 15 46079 2174 34908663
Hydrothorax 12.56 12.31 8 46086 497 34910340
White blood cell count decreased 12.55 12.31 186 45908 95259 34815578
Ventricular tachycardia 12.51 12.31 10 46084 26569 34884268
Haematocrit decreased 12.51 12.31 79 46015 32137 34878700
Erythropoiesis abnormal 12.47 12.31 6 46088 214 34910623
Remission not achieved 12.47 12.31 5 46089 114 34910723
Aplasia 12.46 12.31 22 46072 4566 34906271
Cancer surgery 12.45 12.31 8 46086 504 34910333

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 2830.50 12.30 2821 61098 563693 79116776
Drug resistance 1412.58 12.30 685 63234 41528 79638941
Blast crisis in myelogenous leukaemia 983.21 12.30 209 63710 664 79679805
Malignant neoplasm progression 810.70 12.30 751 63168 135239 79545230
Second primary malignancy 803.43 12.30 334 63585 14016 79666453
Cytogenetic analysis abnormal 785.46 12.30 184 63735 1006 79679463
Philadelphia chromosome positive 558.67 12.30 126 63793 564 79679905
Periorbital oedema 385.80 12.30 170 63749 8232 79672237
Pleural effusion 368.40 12.30 515 63404 144747 79535722
Chromosome analysis abnormal 345.18 12.30 71 63848 182 79680287
Acute lymphocytic leukaemia recurrent 333.60 12.30 130 63789 4594 79675875
Gene mutation identification test positive 291.12 12.30 62 63857 199 79680270
Leukaemia recurrent 260.25 12.30 94 63825 2680 79677789
Chronic myeloid leukaemia recurrent 254.02 12.30 57 63862 248 79680221
Neoplasm malignant 248.06 12.30 205 63714 31605 79648864
Gene mutation 240.73 12.30 88 63831 2598 79677871
Oedema 237.13 12.30 378 63541 119202 79561267
Chronic myeloid leukaemia transformation 229.15 12.30 51 63868 212 79680257
Muscle spasms 212.55 12.30 447 63472 174283 79506186
Product substitution issue 184.47 12.30 143 63776 20113 79660356
Disease progression 181.99 12.30 434 63485 183928 79496541
Therapeutic response decreased 173.70 12.30 240 63679 66613 79613856
Eyelid oedema 173.36 12.30 118 63801 13569 79666900
Metastases to liver 165.63 12.30 155 63764 28159 79652310
Completed suicide 154.53 12.30 11 63908 245756 79434713
Rheumatoid arthritis 144.76 12.30 5 63914 208465 79472004
Thrombocytopenia 144.28 12.30 504 63415 264755 79415714
Cytogenetic abnormality 143.70 12.30 48 63871 1077 79679392
Bone marrow failure 138.07 12.30 187 63732 50920 79629549
Face oedema 136.45 12.30 139 63780 27997 79652472
Chronic myeloid leukaemia 133.11 12.30 63 63856 3601 79676868
Fluid retention 129.22 12.30 214 63705 69595 79610874
Recurrent cancer 128.51 12.30 56 63863 2637 79677832
Polymerase chain reaction positive 126.05 12.30 33 63886 302 79680167
Blast cell crisis 124.01 12.30 28 63891 126 79680343
Chronic graft versus host disease 122.09 12.30 73 63846 6708 79673761
Splenomegaly 120.20 12.30 113 63806 20641 79659828
Fall 118.29 12.30 130 63789 487499 79192970
Drug abuse 112.59 12.30 4 63915 162687 79517782
Gastric antral vascular ectasia 111.04 12.30 38 63881 920 79679549
Gastrointestinal stromal tumour 108.72 12.30 44 63875 1719 79678750
Generalised oedema 107.52 12.30 113 63806 23596 79656873
Pancytopenia 105.24 12.30 332 63587 165413 79515056
Drug hypersensitivity 102.46 12.30 56 63863 298860 79381609
Eye swelling 102.35 12.30 116 63803 26352 79654117
Growth retardation 101.25 12.30 43 63876 1900 79678569
Arthropathy 100.45 12.30 12 63907 177099 79503370
Myelofibrosis 100.16 12.30 46 63873 2454 79678015
Neoplasm recurrence 99.07 12.30 54 63865 4160 79676309
Hypotension 98.60 12.30 125 63794 440192 79240277
Graft versus host disease 97.12 12.30 87 63832 14939 79665530
Anaemia 96.82 12.30 649 63270 444366 79236103
Nausea 95.68 12.30 1178 62741 956018 78724451
White blood cell count increased 93.03 12.30 193 63726 74440 79606029
Blast cells present 92.59 12.30 33 63886 904 79679565
Bone marrow necrosis 92.36 12.30 25 63894 263 79680206
Drug intolerance 88.92 12.30 433 63486 263686 79416783
Pericardial effusion 87.24 12.30 143 63776 46094 79634375
Injection site pain 87.12 12.30 4 63915 129834 79550635
Oedema peripheral 85.93 12.30 415 63504 251873 79428596
Therapy non-responder 84.26 12.30 211 63708 92094 79588375
Therapeutic product effect decreased 83.90 12.30 15 63904 163848 79516621
Bone pain 83.83 12.30 156 63763 55586 79624883
Pain 83.10 12.30 288 63631 703514 78976955
Blast cell count increased 82.87 12.30 34 63885 1376 79679093
Platelet count decreased 82.69 12.30 342 63577 194322 79486147
Haematotoxicity 81.37 12.30 80 63839 15439 79665030
Metastases to peritoneum 81.15 12.30 48 63871 4324 79676145
Pseudoporphyria 81.03 12.30 27 63892 601 79679868
Acquired gene mutation 79.91 12.30 38 63881 2195 79678274
Haemoglobin decreased 78.98 12.30 370 63549 221749 79458720
Confusional state 75.68 12.30 86 63833 317911 79362558
Overdose 74.89 12.30 27 63892 184179 79496290
Neoplasm progression 74.44 12.30 142 63777 51540 79628929
Neutropenia 72.63 12.30 436 63483 287274 79393195
Hepatotoxicity 72.62 12.30 140 63779 51212 79629257
Thrombocytosis 70.76 12.30 57 63862 8469 79672000
Rash 70.73 12.30 741 63178 577617 79102852
Central nervous system leukaemia 69.99 12.30 22 63897 404 79680065
Desmoid tumour 67.19 12.30 17 63902 134 79680335
Sinusitis 66.41 12.30 37 63882 195464 79485005
Necrotising panniculitis 64.15 12.30 14 63905 52 79680417
Off label use 63.77 12.30 446 63473 906769 78773700
Conjunctival haemorrhage 63.63 12.30 46 63873 5819 79674650
Leukocytosis 60.87 12.30 118 63801 43337 79637132
Clonal evolution 59.95 12.30 17 63902 215 79680254
Joint swelling 59.43 12.30 87 63832 288559 79391910
Product use issue 58.87 12.30 49 63870 209773 79470696
Intentional overdose 58.08 12.30 8 63911 105952 79574517
Condition aggravated 57.75 12.30 207 63712 500917 79179552
Tumour necrosis 57.67 12.30 29 63890 1893 79678576
Stem cell transplant 56.81 12.30 36 63883 3668 79676801
Musculoskeletal stiffness 56.78 12.30 35 63884 174973 79505496
Discomfort 55.31 12.30 16 63903 125601 79554868
Nasopharyngitis 54.77 12.30 74 63845 253807 79426662
Cytopenia 54.15 12.30 74 63845 20309 79660160
Swelling face 54.02 12.30 152 63767 71060 79609409
Therapy partial responder 53.71 12.30 68 63851 17329 79663140
Blood lactate dehydrogenase increased 53.20 12.30 105 63814 39065 79641404
Asthma 52.90 12.30 21 63898 135074 79545395
Blood pressure increased 52.64 12.30 55 63864 211305 79469164
Gastrointestinal toxicity 52.50 12.30 47 63872 8062 79672407
Inappropriate schedule of product administration 51.95 12.30 21 63898 133607 79546862
Normal newborn 51.85 12.30 44 63875 7028 79673441
Urinary tract infection 51.52 12.30 88 63831 274424 79406045
Injection site erythema 50.59 12.30 3 63916 78194 79602275
Psoriatic arthropathy 50.44 12.30 3 63916 77996 79602473
Oral pigmentation 50.33 12.30 10 63909 20 79680449
Arthritis 49.91 12.30 15 63904 114865 79565604
Bone marrow transplant 49.86 12.30 24 63895 1424 79679045
Loss of personal independence in daily activities 49.14 12.30 11 63908 102569 79577900
Tumour excision 48.71 12.30 18 63901 548 79679921
Surgery 48.38 12.30 91 63828 32675 79647794
Glossodynia 47.69 12.30 12 63907 103325 79577144
Diarrhoea 47.08 12.30 977 62942 879512 78800957
Endocarditis noninfective 46.75 12.30 14 63905 217 79680252
Ascites 46.66 12.30 150 63769 75412 79605057
Trisomy 8 46.35 12.30 9 63910 15 79680454
Central nervous system neoplasm 46.21 12.30 12 63907 106 79680363
Lower respiratory tract infection 46.02 12.30 23 63896 129197 79551272
Chronic graft versus host disease in skin 45.04 12.30 23 63896 1551 79678918
Peripheral arterial occlusive disease 44.09 12.30 43 63876 8215 79672254
Wound 43.97 12.30 19 63900 116160 79564309
Chloroma 43.33 12.30 18 63901 752 79679717
Dizziness 42.93 12.30 247 63672 526194 79154275
White blood cell count decreased 42.26 12.30 277 63642 188011 79492458
Myalgia 42.21 12.30 274 63645 185367 79495102
Mobility decreased 41.65 12.30 23 63896 122152 79558317
Toxicity to various agents 41.63 12.30 185 63734 421355 79259114
Duodenal ulcer perforation 41.47 12.30 3 63916 66208 79614261
Bradycardia 41.40 12.30 29 63890 135528 79544941
Helicobacter infection 41.35 12.30 4 63915 69700 79610769
Loss of therapeutic response 40.94 12.30 18 63901 866 79679603
Vomiting 40.64 12.30 754 63165 665074 79015395
Tumour rupture 40.37 12.30 15 63904 464 79680005
Anaphylactic reaction 40.07 12.30 9 63910 83734 79596735
Cardiotoxicity 39.63 12.30 49 63870 12190 79668279
Tumour haemorrhage 39.35 12.30 30 63889 4114 79676355
Pneumatosis intestinalis 39.30 12.30 36 63883 6361 79674108
Metastasis 38.95 12.30 37 63882 6843 79673626
Urticaria 38.91 12.30 55 63864 185146 79495323
Anxiety 38.59 12.30 89 63830 248423 79432046
Aplasia 38.57 12.30 39 63880 7781 79672688
Hypersensitivity 38.28 12.30 97 63822 262142 79418327
Carotid intima-media thickness increased 38.25 12.30 10 63909 91 79680378
Toxic skin eruption 38.12 12.30 66 63853 22227 79658242
Platelet dysfunction 37.83 12.30 14 63905 428 79680041
Scleroderma 37.79 12.30 33 63886 5477 79674992
Bone marrow oedema 37.68 12.30 21 63898 1690 79678779
Delirium 36.85 12.30 11 63908 84616 79595853
Pulmonary aplasia 36.78 12.30 6 63913 0 79680469
Erythrocyanosis 36.78 12.30 6 63913 0 79680469
Somnolence 36.77 12.30 86 63833 238895 79441574
Chylothorax 36.60 12.30 16 63903 759 79679710
Eye oedema 36.60 12.30 22 63897 2041 79678428
Pubertal failure 35.93 12.30 7 63912 12 79680457
Drug clearance decreased 35.88 12.30 26 63893 3301 79677168
Hyperkalaemia 35.56 12.30 24 63895 114374 79566095
Suicidal ideation 34.96 12.30 9 63910 76331 79604138
Post embolisation syndrome 34.61 12.30 9 63910 80 79680389
Ankle brachial index decreased 34.61 12.30 9 63910 80 79680389
Colon cancer 34.53 12.30 50 63869 14473 79665996
Graft versus host disease in eye 34.44 12.30 12 63907 307 79680162
Pulse waveform abnormal 34.31 12.30 9 63910 83 79680386
Acute kidney injury 34.11 12.30 260 63659 519144 79161325
Hallucination 34.11 12.30 13 63906 85732 79594737
Flushing 34.10 12.30 14 63905 88254 79592215
Platelet count increased 34.04 12.30 63 63856 22343 79658126
Injury 33.87 12.30 10 63909 77486 79602983
Cardiac output decreased 33.64 12.30 20 63899 1818 79678651
Skin fragility 33.63 12.30 16 63903 925 79679544
Intentional product use issue 33.13 12.30 44 63875 152068 79528401
Therapy change 33.07 12.30 35 63884 7364 79673105
Wheezing 33.01 12.30 27 63892 116637 79563832
Skin hypopigmentation 32.78 12.30 16 63903 979 79679490
Janus kinase 2 mutation 32.63 12.30 6 63913 6 79680463
Acute lymphocytic leukaemia 32.56 12.30 29 63890 4940 79675529
Syncope 32.32 12.30 59 63860 179390 79501079
Impaired healing 32.12 12.30 15 63904 87640 79592829
Psoriasis 31.81 12.30 16 63903 89571 79590898
Ill-defined disorder 31.67 12.30 7 63912 65868 79614601
Cerebral toxoplasmosis 31.43 12.30 21 63898 2341 79678128
Lacrimation increased 31.43 12.30 61 63858 22416 79658053
Treatment failure 31.34 12.30 239 63680 170247 79510222
Chronic myeloid leukaemia (in remission) 30.90 12.30 6 63913 10 79680459
Sleep disorder 30.88 12.30 15 63904 85662 79594807
Pituitary apoplexy 30.87 12.30 10 63909 203 79680266
Pemphigus 30.81 12.30 21 63898 99561 79580908
Therapeutic response delayed 30.69 12.30 16 63903 1126 79679343
Suicide attempt 30.69 12.30 14 63905 82918 79597551
Slit-lamp tests abnormal 30.65 12.30 5 63914 0 79680469
Blood pressure fluctuation 30.59 12.30 8 63911 67137 79613332
Papilloedema 30.59 12.30 31 63888 6202 79674267
Leukaemia 30.05 12.30 30 63889 5895 79674574
Right ventricular diastolic collapse 29.92 12.30 8 63911 80 79680389
Eye haemorrhage 29.90 12.30 38 63881 9719 79670750
Tremor 29.67 12.30 57 63862 170026 79510443
Arterial disorder 29.67 12.30 19 63900 1971 79678498
Disseminated intravascular coagulation 29.66 12.30 79 63840 35763 79644706
Pericarditis 29.64 12.30 24 63895 104212 79576257
Exposure via father 29.48 12.30 8 63911 85 79680384
Jaw operation 29.34 12.30 14 63905 815 79679654
Metabolic acidosis 28.91 12.30 15 63904 82514 79597955
Eosinophilia 28.89 12.30 91 63828 45254 79635215
Hypertension 28.74 12.30 152 63767 330840 79349629
Pulmonary embolism 28.68 12.30 59 63860 171595 79508874
Acute graft versus host disease 28.66 12.30 38 63881 10129 79670340
Blood bilirubin increased 28.58 12.30 117 63802 66115 79614354
Folliculitis 28.48 12.30 5 63914 55375 79625094
Mucosal inflammation 28.37 12.30 128 63791 75452 79605017
Agitation 28.30 12.30 23 63896 99692 79580777
Sedation 28.24 12.30 4 63915 51891 79628578
Blood cholesterol increased 28.19 12.30 16 63903 83704 79596765
Osteonecrosis of external auditory canal 28.15 12.30 9 63910 175 79680294
Skin toxicity 28.08 12.30 34 63885 8280 79672189
Pyrexia 28.07 12.30 727 63192 677982 79002487
Medication error 27.99 12.30 10 63909 68632 79611837
Headache 27.96 12.30 363 63556 653409 79027060
Back pain 27.93 12.30 137 63782 304043 79376426
Disease recurrence 27.62 12.30 88 63831 44021 79636448
Osteoarthritis 27.56 12.30 18 63901 87291 79593178
Lactic acidosis 27.43 12.30 11 63908 70348 79610121
Heart rate decreased 27.41 12.30 11 63908 70305 79610164
Deep vein thrombosis 27.34 12.30 34 63885 120885 79559584
Irritable bowel syndrome 27.26 12.30 8 63911 62233 79618236
Loss of CAR T-cell persistence 27.14 12.30 6 63913 24 79680445
Malaise 26.87 12.30 257 63662 489612 79190857
Chronic obstructive pulmonary disease 26.44 12.30 18 63901 85401 79595068
Therapy cessation 26.38 12.30 78 63841 37484 79642985
Metamyelocyte count increased 26.34 12.30 12 63907 628 79679841
Hyperhidrosis 26.23 12.30 51 63868 151441 79529028
Hepatomegaly 26.12 12.30 51 63868 18823 79661646
Blood creatinine increased 26.09 12.30 213 63706 154844 79525625
Hyponatraemia 25.78 12.30 66 63853 177782 79502687
Gastric cancer 25.60 12.30 36 63883 10143 79670326
Acute myeloid leukaemia 25.48 12.30 68 63851 30817 79649652
Interstitial lung disease 25.45 12.30 166 63753 112434 79568035
Blood pressure systolic increased 25.27 12.30 11 63908 66975 79613494
Growth failure 25.24 12.30 9 63910 247 79680222
Prostate cancer 25.21 12.30 71 63848 33197 79647272
Insomnia 25.15 12.30 106 63813 245064 79435405
Cardio-respiratory arrest 25.07 12.30 30 63889 108480 79571989
Parakeratosis 24.87 12.30 10 63909 384 79680085
Lactose intolerance 24.65 12.30 18 63901 2312 79678157
Obliterative bronchiolitis 24.61 12.30 20 63899 3008 79677461
Intentional product misuse 24.55 12.30 24 63895 95141 79585328
Acute aortic syndrome 24.52 12.30 4 63915 0 79680469
Philadelphia chromosome negative 24.52 12.30 4 63915 0 79680469
Jaundice 24.42 12.30 96 63823 53253 79627216
Rhabdomyolysis 24.38 12.30 28 63891 103103 79577366
Stress 24.34 12.30 17 63902 79595 79600874
Knee arthroplasty 24.33 12.30 3 63916 43245 79637224
Myelodysplastic syndrome 24.28 12.30 66 63853 30235 79650234
Renal tuberculosis 24.09 12.30 6 63913 44 79680425
Pigmentation disorder 24.09 12.30 26 63893 5592 79674877
Transdifferentiation of neoplasm 23.84 12.30 7 63912 101 79680368
Liver disorder 23.79 12.30 118 63801 72299 79608170
Pericardial excision 23.63 12.30 6 63913 48 79680421
Oxygen saturation decreased 23.61 12.30 42 63877 129005 79551464
Multiple-drug resistance 23.43 12.30 32 63887 8776 79671693
Orthostatic hypotension 23.21 12.30 8 63911 56156 79624313
Cancer surgery 23.12 12.30 12 63907 837 79679632
Red blood cell count decreased 22.79 12.30 99 63820 57414 79623055
Marrow hyperplasia 22.77 12.30 15 63904 1633 79678836
Presyncope 22.73 12.30 3 63916 41051 79639418
Ileus paralytic 22.69 12.30 33 63886 9587 79670882
Pneumonia 22.54 12.30 383 63536 659863 79020606
Product use in unapproved indication 22.20 12.30 302 63617 250057 79430412
Hepatic calcification 21.96 12.30 9 63910 363 79680106
Leukopenia 21.77 12.30 164 63755 116349 79564120
Lichen planus 21.77 12.30 18 63901 2773 79677696
Ocular myasthenia 21.62 12.30 9 63910 378 79680091
Lactobacillus infection 21.47 12.30 9 63910 385 79680084
Myelocyte count increased 21.32 12.30 11 63908 758 79679711
Gastrectomy 21.25 12.30 10 63909 564 79679905
International normalised ratio increased 21.13 12.30 22 63897 84699 79595770
Costal cartilage fracture 21.13 12.30 8 63911 261 79680208
Adrenomegaly 21.10 12.30 9 63910 402 79680067
Blood alkaline phosphatase increased 21.10 12.30 104 63815 63560 79616909
Contusion 20.95 12.30 56 63863 148720 79531749
Bone marrow disorder 20.90 12.30 19 63900 3324 79677145
Paraesthesia 20.81 12.30 72 63847 176251 79504218
Hepatosplenomegaly 20.79 12.30 25 63894 6044 79674425
Acute myeloid leukaemia recurrent 20.71 12.30 19 63900 3364 79677105
Aspiration pleural cavity 20.61 12.30 14 63905 1603 79678866
Left ventricular dysfunction 20.61 12.30 47 63872 19314 79661155
Type 2 diabetes mellitus 20.58 12.30 10 63909 57112 79623357
Pseudomyxoma peritonei 20.48 12.30 4 63915 7 79680462
Haemorrhagic ascites 20.46 12.30 8 63911 285 79680184
Generalised tonic-clonic seizure 20.45 12.30 5 63914 43905 79636564
Skin exfoliation 20.44 12.30 93 63826 55007 79625462
Metastases to heart 20.41 12.30 8 63911 287 79680182
Philadelphia positive chronic myeloid leukaemia 20.36 12.30 7 63912 172 79680297
Therapy responder 20.26 12.30 9 63910 444 79680025
Product dose omission issue 20.20 12.30 116 63803 247421 79433048
Urine odour abnormal 20.13 12.30 25 63894 6248 79674221
Skin depigmentation 20.11 12.30 12 63907 1098 79679371
Nasal congestion 20.10 12.30 19 63900 76533 79603936
Optic neuritis 20.09 12.30 31 63888 9489 79670980
Basophilia 20.04 12.30 5 63914 37 79680432
Concomitant disease aggravated 19.97 12.30 37 63882 13130 79667339
Delayed puberty 19.88 12.30 7 63912 185 79680284
Rhinorrhoea 19.84 12.30 19 63900 76055 79604414
Large intestine infection 19.79 12.30 18 63901 3151 79677318
Chest expansion decreased 19.77 12.30 7 63912 188 79680281
Unresponsive to stimuli 19.75 12.30 10 63909 55778 79624691
Arthralgia 19.73 12.30 331 63588 571472 79108997
Neoplasm 19.68 12.30 30 63889 9086 79671383
Right ventricular failure 19.65 12.30 52 63867 23445 79657024
Angiocentric lymphoma 19.59 12.30 11 63908 898 79679571
Lichenoid keratosis 19.58 12.30 20 63899 4037 79676432
Intestinal congestion 19.52 12.30 4 63915 10 79680459
Feeling hot 19.28 12.30 12 63907 59722 79620747
Pyoderma gangrenosum 19.17 12.30 20 63899 4138 79676331
Periorbital swelling 19.17 12.30 17 63902 2879 79677590
Cardiac arrest 19.17 12.30 72 63847 172024 79508445
Tumour lysis syndrome 19.04 12.30 52 63867 23887 79656582
Ejection fraction decreased 18.99 12.30 66 63853 34511 79645958
Spleen palpable 18.98 12.30 4 63915 12 79680457
Bursitis 18.96 12.30 3 63916 35841 79644628
Haematocrit decreased 18.80 12.30 98 63821 61214 79619255
Polycythaemia vera 18.57 12.30 8 63911 366 79680103
Mucosal pigmentation 18.39 12.30 3 63916 0 79680469
Fibrin D dimer decreased 18.39 12.30 3 63916 0 79680469
Blood blister 18.38 12.30 17 63902 3040 79677429
Polymerase chain reaction 18.38 12.30 6 63913 125 79680344
Chronic lymphocytic leukaemia 18.26 12.30 21 63898 4845 79675624
Balance disorder 18.24 12.30 32 63887 98825 79581644
Demyelination 18.17 12.30 27 63892 7996 79672473
Intra-abdominal haemorrhage 17.72 12.30 20 63899 4520 79675949
Myopathy toxic 17.66 12.30 11 63908 1087 79679382
Acinetobacter sepsis 17.65 12.30 5 63914 63 79680406
COVID-19 17.53 12.30 66 63853 157608 79522861
Hepatic enzyme increased 17.48 12.30 81 63838 182529 79497940
Seizure 17.35 12.30 85 63834 188749 79491720
Diaphragmatic disorder 17.35 12.30 13 63906 1737 79678732
Mental status changes 17.14 12.30 17 63902 66942 79613527
Swelling of eyelid 16.98 12.30 18 63901 3793 79676676
Anaphylactic shock 16.95 12.30 4 63915 35992 79644477
Adverse event 16.95 12.30 14 63905 60200 79620269
Computerised tomogram abnormal 16.79 12.30 17 63902 3396 79677073
Retroperitoneal fibrosis 16.62 12.30 9 63910 684 79679785
Lung infiltration 16.49 12.30 48 63871 22864 79657605
Coma 16.46 12.30 35 63884 100614 79579855
Tyrosine kinase mutation 16.22 12.30 4 63915 28 79680441
Incorrect route of product administration 16.22 12.30 4 63915 34925 79645544
Retinal vascular disorder 16.20 12.30 7 63912 323 79680146
Myeloproliferative neoplasm 16.14 12.30 10 63909 979 79679490
Bone metabolism disorder 16.08 12.30 8 63911 510 79679959
Leukaemic infiltration extramedullary 16.04 12.30 6 63913 189 79680280
Oncologic complication 15.98 12.30 7 63912 334 79680135
Blood fibrinogen decreased 15.93 12.30 13 63906 1966 79678503
Bone marrow leukaemic cell infiltration 15.87 12.30 4 63915 31 79680438
Accidental exposure to product 15.74 12.30 3 63916 31319 79649150
Diabetic ketoacidosis 15.67 12.30 4 63915 34118 79646351
Alveolar proteinosis 15.53 12.30 9 63910 780 79679689
Chronic graft versus host disease in intestine 15.52 12.30 7 63912 358 79680111
Blindness 15.44 12.30 54 63865 28329 79652140
Aggression 15.42 12.30 11 63908 50947 79629522
Stenotrophomonas infection 15.38 12.30 17 63902 3756 79676713
Psychotic disorder 15.30 12.30 7 63912 41395 79639074
Cardiac tamponade 15.26 12.30 27 63892 9249 79671220
Nephrotic syndrome 15.22 12.30 30 63889 11144 79669325
Loss of consciousness 15.19 12.30 76 63843 167867 79512602
Cystitis 15.17 12.30 12 63907 52720 79627749
Red blood cell sedimentation rate increased 15.15 12.30 9 63910 45933 79634536
Oesophagectomy 15.10 12.30 3 63916 6 79680463
Blood pressure systolic inspiratory decreased 15.10 12.30 3 63916 6 79680463
C-kit gene mutation 15.10 12.30 3 63916 6 79680463
Bone neoplasm 14.95 12.30 9 63910 837 79679632
Epistaxis 14.94 12.30 43 63876 111472 79568997
Subcutaneous emphysema 14.90 12.30 12 63907 1782 79678687
Eczema asteatotic 14.90 12.30 8 63911 598 79679871
Breast oedema 14.87 12.30 4 63915 41 79680428
Karyotype analysis abnormal 14.87 12.30 4 63915 41 79680428
Acute graft versus host disease in skin 14.87 12.30 24 63895 7634 79672835
Renal disorder 14.83 12.30 70 63849 42035 79638434
Concomitant disease progression 14.77 12.30 16 63903 3457 79677012
Hydrothorax 14.77 12.30 11 63908 1457 79679012
Allogenic bone marrow transplantation therapy 14.70 12.30 4 63915 43 79680426
Cellulitis 14.65 12.30 42 63877 109018 79571451
Cardiac failure 14.63 12.30 189 63730 154653 79525816
B-cell small lymphocytic lymphoma 14.54 12.30 5 63914 123 79680346
Intentional self-injury 14.50 12.30 4 63915 32415 79648054
Retroplacental haematoma 14.46 12.30 5 63914 125 79680344
Bone development abnormal 14.38 12.30 4 63915 47 79680422
Influenza like illness 14.36 12.30 22 63897 71685 79608784
Lipase increased 14.34 12.30 37 63882 16429 79664040
Skin hyperpigmentation 14.33 12.30 23 63896 7280 79673189
Graft versus host disease in lung 14.33 12.30 9 63910 903 79679566
Metastases to gastrointestinal tract 14.27 12.30 5 63914 130 79680339
Dysarthria 14.27 12.30 20 63899 67602 79612867
Myocardial ischaemia 14.27 12.30 49 63870 25470 79654999
Lymphadenopathy 14.24 12.30 82 63837 53165 79627304
Chronic graft versus host disease in liver 14.18 12.30 8 63911 659 79679810
Oropharyngeal cancer 14.17 12.30 5 63914 133 79680336
Myelocytosis 14.15 12.30 4 63915 50 79680419
Polyserositis 13.98 12.30 8 63911 677 79679792
Thrombosis 13.96 12.30 29 63890 84071 79596398
Migraine 13.84 12.30 31 63888 87462 79593007
Leukaemic infiltration 13.83 12.30 5 63914 143 79680326
Clear cell sarcoma of soft tissue 13.78 12.30 3 63916 11 79680458
Typhoid fever 13.73 12.30 4 63915 56 79680413
Tachycardia 13.60 12.30 85 63834 177683 79502786
Complex regional pain syndrome 13.51 12.30 12 63907 2036 79678433
Depression 13.50 12.30 110 63809 216680 79463789
Atrial fibrillation 13.46 12.30 98 63821 197788 79482681
Abdominal pain 13.44 12.30 408 63511 389161 79291308
Acoustic neuroma 13.34 12.30 6 63913 305 79680164
Azoospermia 13.30 12.30 5 63914 160 79680309
Biopsy bone marrow abnormal 13.25 12.30 7 63912 506 79679963
Polyhydramnios 13.22 12.30 11 63908 1709 79678760
Essential thrombocythaemia 13.21 12.30 5 63914 163 79680306
Liver abscess 13.18 12.30 20 63899 6034 79674435
Myoclonus 13.17 12.30 3 63916 27657 79652812
Skin neoplasm excision 13.17 12.30 9 63910 1041 79679428
Tumour compression 13.15 12.30 5 63914 165 79680304
Transitional cell carcinoma 13.13 12.30 13 63906 2528 79677941
Haemangioma 13.12 12.30 13 63906 2532 79677937
Hepatic necrosis 13.09 12.30 25 63894 9075 79671394
Hypomagnesaemia 13.09 12.30 11 63908 46900 79633569
Oligoasthenozoospermia 13.03 12.30 3 63916 15 79680454
Toxic epidermal necrolysis 13.00 12.30 10 63909 44571 79635898
Histology abnormal 12.94 12.30 6 63913 327 79680142
Splenectomy 12.88 12.30 8 63911 787 79679682
Constipation 12.87 12.30 155 63764 282895 79397574
Hypereosinophilic syndrome 12.82 12.30 7 63912 541 79679928
Pneumonia fungal 12.81 12.30 28 63891 11182 79669287
Histiocytic sarcoma 12.80 12.30 4 63915 72 79680397
Dropped head syndrome 12.79 12.30 6 63913 336 79680133
General physical health deterioration 12.79 12.30 150 63769 275088 79405381
Feeling abnormal 12.77 12.30 75 63844 159124 79521345
Myelosuppression 12.77 12.30 65 63854 40231 79640238
Chest discomfort 12.76 12.30 62 63857 137982 79542487
Bone formation decreased 12.70 12.30 4 63915 74 79680395
Skin mass 12.66 12.30 23 63896 8040 79672429
Autoimmune lymphoproliferative syndrome 12.64 12.30 5 63914 184 79680285
Bronchopulmonary aspergillosis 12.63 12.30 43 63876 22251 79658218
Speech disorder 12.63 12.30 15 63904 54430 79626039
Skin atrophy 12.60 12.30 19 63900 5699 79674770
Myeloblast count increased 12.57 12.30 3 63916 18 79680451
Gastric neoplasm 12.48 12.30 6 63913 355 79680114
Alopecia 12.39 12.30 122 63797 231233 79449236
Liver carcinoma ruptured 12.39 12.30 5 63914 194 79680275
Urosepsis 12.37 12.30 3 63916 26492 79653977
Subdural haematoma evacuation 12.36 12.30 4 63915 81 79680388
Bronchiolitis 12.34 12.30 16 63903 4172 79676297

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EA01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
BCR-ABL tyrosine kinase inhibitors
FDA MoA N0000020009 Bcr-Abl Tyrosine Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:68495 Type I cell-death inducers
CHEBI has role CHEBI:149553 anticoronaviral drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Dermatofibrosarcoma protuberans indication 276799004
Systemic mast cell disease indication 397016004 DOID:349
Blastic phase chronic myeloid leukemia indication 413656006
Chronic eosinophilic leukemia indication 413836008
Chronic phase chronic myeloid leukemia indication 413847001
Gastrointestinal stromal tumor indication 420120006 DOID:9253
Idiopathic hypereosinophilic syndrome indication 423294001
Philadelphia chromosome-positive acute lymphoblastic leukemia indication 425688002
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication 449108003
Myelodysplastic/myeloproliferative diseases with re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR) indication 738527001
Chronic Myelocytic Leukemia Accelerated Phase indication
Heart valve disorder contraindication 368009 DOID:4079
Cerebral edema contraindication 2032001
Hypophosphatemia contraindication 4996001
Congenital heart disease contraindication 13213009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Pulmonary edema contraindication 19242006 DOID:11396
Hypertensive disorder contraindication 38341003 DOID:10763
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Myocarditis contraindication 50920009 DOID:820
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Bleeding contraindication 131148009
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Pericardial effusion contraindication 373945007 DOID:118
Purpuric disorder contraindication 387778001
Ascites contraindication 389026000
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Pleural Effusions contraindication
Chronic Heart Failure Following Myocardial Infarction contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.96 acidic
pKa2 8.49 Basic
pKa3 4.34 Basic
pKa4 3.73 Basic
pKa5 2.2 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.85 CHEMBL CHEMBL
Tyrosine-protein kinase ABL1 Kinase INHIBITOR Kd 8.96 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 7.89 CHEMBL CHEMBL
Histamine H2 receptor GPCR Ki 5.71 DRUG MATRIX
Carbonic anhydrase 2 Enzyme Ki 7.52 CHEMBL
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
ATP-binding cassette sub-family G member 2 Transporter IC50 5.47 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 7.50 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 5.34 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme IC50 6.40 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.12 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 6.01 CHEMBL
Epidermal growth factor receptor Kinase Kd 5.12 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 4.69 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 4.77 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 6.96 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Ki 4.51 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 7.40 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.51 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 5.77 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 5.48 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 5.20 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 4.59 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.96 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.51 CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 10.22 CHEMBL
Insulin receptor Kinase AGONIST Ki 5 PDSP
Thromboxane-A synthase Enzyme IC50 6.70 DRUG MATRIX
Mitogen-activated protein kinase 8 Kinase Kd 5.49 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 6.28 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 6.41 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.51 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Ki 5 PDSP
Tyrosine-protein kinase SYK Kinase IC50 5.30 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.05 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Ki 5 PDSP
Carbonic anhydrase 14 Enzyme Ki 6.33 CHEMBL
Fibroblast growth factor receptor 1 Kinase Ki 5 PDSP
Serine/threonine-protein kinase PLK4 Kinase Kd 5.11 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 8.22 CHEMBL
Fibroblast growth factor receptor 2 Kinase Ki 5 PDSP
Serine/threonine-protein kinase 17A Kinase Kd 5.55 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.62 CHEMBL
Mitogen-activated protein kinase 14 Kinase IC50 4.86 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 5.82 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.35 CHEMBL
Cyclin-G-associated kinase Kinase Kd 6 CHEMBL
Ephrin type-B receptor 1 Kinase Ki 5 PDSP
Dual specificity protein kinase CLK4 Kinase Kd 5.68 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.28 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 9.15 CHEMBL
Ephrin type-B receptor 4 Kinase Ki 5 PDSP
Lysine--tRNA ligase Enzyme Ki 5.30 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 5.06 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 5.59 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 5.42 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 5.37 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 7.82 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.28 CHEMBL
Cyclin-dependent kinase 19 Kinase Kd 5.26 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 6.02 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 5.92 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 6.42 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 5.38 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 7.40 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 6.46 CHEMBL
Solute carrier family 22 member 3 Transporter IC50 4.59 CHEMBL
Platelet-derived growth factor receptor Kinase IC50 7.30 CHEMBL
Tyrosine-protein kinase ABL Kinase IC50 7.40 CHEMBL
Bcr/Abl fusion protein Kinase Ki 7.85 CHEMBL
Multidrug resistance protein 1 Transporter IC50 5.14 CHEMBL
ATP-dependent RNA helicase DDX3X Enzyme Kd 6.36 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.13 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.27 DRUG MATRIX
Carbonic anhydrase 13 Enzyme Ki 5.13 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.11 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 5.56 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 7.97 CHEMBL
Platelet-derived growth factor receptor beta Kinase IC50 6.79 CHEMBL

External reference:

IDSource
4021257 VUID
N0000148698 NUI
D01441 KEGG_DRUG
220127-57-1 SECONDARY_CAS_RN
4021257 VANDF
4021258 VANDF
C0939537 UMLSCUI
CHEBI:45783 CHEBI
STI PDB_CHEM_ID
CHEMBL941 ChEMBL_ID
CHEMBL1642 ChEMBL_ID
D000068877 MESH_DESCRIPTOR_UI
DB00619 DRUGBANK_ID
5687 IUPHAR_LIGAND_ID
8031 INN_ID
BKJ8M8G5HI UNII
5291 PUBCHEM_CID
282386 RXNORM
16030 MMSL
238904 MMSL
41395 MMSL
d04758 MMSL
009151 NDDF
009152 NDDF
129558005 SNOMEDCT_US
391634008 SNOMEDCT_US
414460008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0248 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0248 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0248 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0248 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0249 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0249 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0249 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0249 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0401 TABLET 100 mg ORAL NDA 32 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0401 TABLET 100 mg ORAL NDA 32 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0401 TABLET 100 mg ORAL NDA 32 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0401 TABLET 100 mg ORAL NDA 32 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0649 TABLET 400 mg ORAL NDA 32 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0649 TABLET 400 mg ORAL NDA 32 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0649 TABLET 400 mg ORAL NDA 32 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0649 TABLET 400 mg ORAL NDA 32 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7629 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7629 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7630 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7630 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2245 TABLET, FILM COATED 100 mg ORAL ANDA 31 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2245 TABLET, FILM COATED 100 mg ORAL ANDA 31 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2245 TABLET, FILM COATED 100 mg ORAL ANDA 31 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2246 TABLET, FILM COATED 400 mg ORAL ANDA 31 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2246 TABLET, FILM COATED 400 mg ORAL ANDA 31 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2246 TABLET, FILM COATED 400 mg ORAL ANDA 31 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6621 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6621 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6901 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6901 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections